The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo

被引：42
|
作者：
Keren, Aviad [1 ]
Shemer, Avner [1 ]
Ullmann, Yehuda [1 ]
Paus, Ralf [2 ,3 ]
Gilhar, Amos [1 ]
机构：
[1] Technion Israel Inst Technol, Fac Med, Flieman Med Ctr, Skin Res Lab, IL-31096 Haifa, Israel
[2] Univ Manchester, Ctr Dermatol Res, Inst Inflammat & Repair, Manchester, Lancs, England
[3] Univ Munster, Dept Dermatol, D-48149 Munster, Germany
来源：
JOURNAL OF DERMATOLOGICAL SCIENCE | 2015年 / 77卷 / 01期
关键词：
MODEL;
D O I：
10.1016/j.jdermsci.2014.11.009
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：74 / 76
页数：3
相关论文
共 50 条
  • [31] Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells
    Qiu-kai Lu
    Chen Fan
    Cai-gui Xiang
    Bing Wu
    Hui-min Lu
    Chun-lan Feng
    Xiao-qian Yang
    Heng Li
    Wei Tang
    Acta Pharmacologica Sinica, 2022, 43 : 376 - 386
  • [32] Drotaverine Inhibitor of PDE4: Reverses the Streptozotocin Induced Alzheimer’s Disease in Mice
    Samra Nazir
    Fareeha Anwar
    Uzma Saleem
    Bashir Ahmad
    Zohaib Raza
    Maham Sanawar
    Artta ur Rehman
    Tariq Ismail
    Neurochemical Research, 2021, 46 : 1814 - 1829
  • [33] DRM02, a novel PDE4 inhibitor, demonstrates activity in multiple skin inflammation models
    Hunt, D.
    Hofland, H. E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S25 - S25
  • [34] Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
    Fiona E McCann
    Andrew C Palfreeman
    Melanie Andrews
    Dany P Perocheau
    Julia J Inglis
    Peter Schafer
    Marc Feldmann
    Richard O Williams
    Fionula M Brennan
    Arthritis Research & Therapy, 12
  • [35] Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog
    Hanton, Gilles
    Sobry, Cecile
    Dagues, Nicolas
    Provost, Jean-Pierre
    Le Net, Jean-Loic
    Comby, Pierre
    Chevalier, Stephan
    TOXICOLOGY LETTERS, 2008, 179 (01) : 15 - 22
  • [36] Combined Effects of the Phosphodiesterase Type 4 (PDE4) Inhibitor, Roflumilast, and the PDE5 Inhibitor, Tadalafil, in Allergen-Induced Airway Hyperresponsiveness (AHR).
    Takeda, K.
    Shiraishi, Y.
    Domenico, J.
    Loader, J. E.
    Sanjar, S.
    Lucas, J. J.
    Gelfand, E. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [37] Repurposing Human PDE4 Inhibitors for Neglected Tropical Diseases. Evaluation of Analogs of the Human PDE4 Inhibitor GSK-256066 as Inhibitors of PDEB1 of Trypanosoma brucei
    Ochiana, Stefan O.
    Bland, Nicholas D.
    Settimo, Luca
    Campbell, Robert K.
    Pollastri, Michael P.
    CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 85 (05) : 549 - 564
  • [38] Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
    McCann, Fiona E.
    Palfreeman, Andrew C.
    Andrews, Melanie
    Perocheau, Dany P.
    Inglis, Julia J.
    Schafer, Peter
    Feldmann, Marc
    Williams, Richard O.
    Brennan, Fionula M.
    ARTHRITIS RESEARCH & THERAPY, 2010, 12 (03)
  • [39] Tyrosine Kinase 2 Inhibition Ameliorates the Phenotype of Lesional Alopecia Areata Scalp Skin Ex Vivo, and Reverses the Induction of Human Alopecia Areata in a Humanized Mouse Model
    Edelkamp, J.
    Rouille, T.
    Kim, J.
    Keren, A.
    Viola-Soehnlein, J.
    Gao, L.
    Gilhar, A.
    Paus, R.
    Catlett, I.
    Bertolini, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S183 - S183
  • [40] Using the PDE4 Inhibitor ABI-4 to Quantify the Relationship Among in Vitro Potency, Ex Vivo Target Occupancy and in Vivo Efficacy
    Hughes, Zoe
    Hedde, Joseph
    Graf, Radka
    Chang, Cheng
    Scott, Liam
    Doran, Shawn
    Schmidt, Christopher
    Chappie, Thomas
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S601 - S602
12345